Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver N Keene

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Pharmaceutical Statistics|October 30, 2018
Strategies for composite estimands in confirmatory clinical trials: Examples from trials in nasal polyps and steroid reductionOliver N Keene
Pharmaceutical Statistics|March 4, 2010
Intent-to-treat analysis in the presence of off-treatment or missing dataOliver N Keene
Statistics in Medicine|November 19, 2002
Alternatives to the hazard ratio in summarizing efficacy in time-to-event studies: an example from influenza trialsOliver N Keene
Pharmaceutical Statistics|November 4, 2006
Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert GroupAlan J Phillips, Oliver N Keene,
Journal of Biopharmaceutical Statistics|January 8, 2014
Subgroups: time to go back to basic statistical principles?Oliver N Keene, Andrew D Garrett
Pharmaceutical Statistics|February 10, 2010
Statistical resource needs to be increased in the European regulatory agenciesOliver N Keene, Sara H Hughes, Nigel Howitt, et al.
Respiratory Medicine|May 4, 2019
Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of ≥150-300 cells/μLSteven W Yancey, Eric S Bradford, Oliver N Keene
Contemporary Clinical Trials|June 29, 2021
Why ITT analysis is not always the answer for estimating treatment effects in clinical trialsOliver N Keene, David Wright, Alan Phillips, et al.
Pharmaceutical Statistics|August 8, 2024
Helle Lynggaard, Oliver N Keene, Tobias Mütze, et al.
Pharmaceutical Statistics|August 23, 2025
The Estimand Framework and Causal Inference: Complementary Not Competing ParadigmsThomas Drury, Jonathan W Bartlett, David Wright, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Pharmaceutical Statistics|October 30, 2018
Strategies for composite estimands in confirmatory clinical trials: Examples from trials in nasal polyps and steroid reductionOliver N Keene
Pharmaceutical Statistics|March 4, 2010
Intent-to-treat analysis in the presence of off-treatment or missing dataOliver N Keene
Statistics in Medicine|November 19, 2002
Alternatives to the hazard ratio in summarizing efficacy in time-to-event studies: an example from influenza trialsOliver N Keene
Pharmaceutical Statistics|November 4, 2006
Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert GroupAlan J Phillips, Oliver N Keene,
Journal of Biopharmaceutical Statistics|January 8, 2014
Subgroups: time to go back to basic statistical principles?Oliver N Keene, Andrew D Garrett
Pharmaceutical Statistics|February 10, 2010
Statistical resource needs to be increased in the European regulatory agenciesOliver N Keene, Sara H Hughes, Nigel Howitt, et al.
Respiratory Medicine|May 4, 2019
Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of ≥150-300 cells/μLSteven W Yancey, Eric S Bradford, Oliver N Keene
Contemporary Clinical Trials|June 29, 2021
Why ITT analysis is not always the answer for estimating treatment effects in clinical trialsOliver N Keene, David Wright, Alan Phillips, et al.
Pharmaceutical Statistics|August 8, 2024
Helle Lynggaard, Oliver N Keene, Tobias Mütze, et al.
Pharmaceutical Statistics|August 23, 2025
The Estimand Framework and Causal Inference: Complementary Not Competing ParadigmsThomas Drury, Jonathan W Bartlett, David Wright, et al.
Pageof 4